N
VIR icon

Natixis’s Vir Biotechnology VIR Stock Holding History

Natixis’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,043
Closed -$290K – 1360
2022
Q3 		$290K Hold
15,043
– – ﹤0.01% 946
2022
Q2 		$383K Sell
15,043
-97,616
-87% -$2.28M ﹤0.01% 969
2022
Q1 		$2.9M Buy
112,659
+30,209
+37% +$896K 0.01% 662
2021
Q4 		$3.45M Sell
82,450
-23,593
-22% -$924K 0.01% 639
2021
Q3 		$4.62M Buy
+106,043
New +$4.59M 0.02% 565
2021
Q2 		– Sell
-173,110
Closed -$8.88M – 1083
2021
Q1 		$8.88M Sell
173,110
-9,602
-5% -$517K 0.03% 400
2020
Q4 		$4.89M Buy
+182,712
New +$5.94M 0.02% 516

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's VIR Position: Q4 2022 in Review

Natixis sold out of Vir Biotechnology (VIR) in Q4 2022, closing a stake of 15,043 shares — an estimated $290K sold.

Natixis first reported a position in VIR in Q4 2020 and held it in 7 quarters. The position peaked at $8.88M in Q1 2021. 223 funds tracked by Wall St. Rank hold VIR as of Q4 2022.

  • Natixis reported no remaining Vir Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Natixis sold 15,043 Vir Biotechnology shares in Q4 2022, an estimated $290K.
  • Natixis first reported a position in Vir Biotechnology in Q4 2020 and held it in 7 quarters.
  • Natixis's Vir Biotechnology position peaked at $8.88M in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.